跳至主要内容
临床试验/NCT00659113
NCT00659113Unknown2 期

A Phase II Trial of a TS-1/Cisplatin Based Definitive Chemoradiotherapy for Resectable Esophageal Cancer

Yonsei University2 个研究点 分布在 2 个国家目标入组 32 人开始时间: 2008年3月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
32
试验地点
2
主要终点
Response rate

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy together with more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving S-1 and cisplatin together with radiation therapy works in treating patients with stage IIA, stage III, or stage IVA esophageal cancer that can be removed by surgery.

详细描述

OBJECTIVES:

Primary

  • To evaluate response rate in patients with stage IIA-IVA resectable esophageal cancer treated with chemoradiotherapy comprising S-1, cisplatin, and radiotherapy.

Secondary

  • To evaluate overall survival of these patients.
  • To evaluate progression-free survival of these patients.
  • To evaluate toxicity in these patients.
  • To correlate initial squamous cell carcinoma antigen and C-reactive protein with response and survival in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Response rate

次要结局

  • Overall survival
  • Progression-free survival
  • Toxicity
  • Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验